« Previous
Next »
American Journal of Cardiology
Volume 104, Issue 6
, Pages 745-749
, 15 September 2009
Impact of Homocysteine-Lowering Vitamin Therapy on Long-Term Outcome of Patients With Coronary Artery Disease
References
- . Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol. 1969;56:111–128
- . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
- . Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022
- . Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286–291
- . Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
- . Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050
- . MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023–2031
- . Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation. 1999;100:2406–2410
- . Homocysteine and the risk of premature coronary heart disease. Circulation. 1996;94:2154–2158
- . Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor coronary artery disease. Circulation. 1997;95:2032–2036
- . Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573–2577
- . Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410–2416
- . Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21–23
- . The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20:295–300
- . The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999;65:59–67
- . Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364
- . Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105–2113
- . Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
- . Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
- . Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–2036
- . Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795–804
- . Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:1163–1170
- . Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379–386
- . Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study. Transplantation. 2008;85:1146–1150
- . Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593–1600
- . Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA. 2002;288:973–979
- . Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673–2681
- . Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
- . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase gene. Nat Genet. 1995;10:111–113
- . Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9–19
This study was supported in part by an institutional research grant from Rabin Medical Center, Petah Tikva, Israel.
PII: S0002-9149(09)01046-7
doi: 10.1016/j.amjcard.2009.05.011
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
American Journal of Cardiology
Volume 104, Issue 6
, Pages 745-749
, 15 September 2009
